Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Befotertinib vs Icotinib in EGFR+ NSCLC
NCT06041776Phase 3Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of befotertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Disease free survival in patients with stage II-IIIB up to 5 years. Started Mar 2023; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06041776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041776.